Verve Therapeutics
Coverage of Verve Therapeutics in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly's gene therapy reduced cholesterol by 62% in a Phase 1 trial, with no serious adverse events. The company acquired the therapy through its $1 billion buyout of Verve Therapeutics and plans Phase 2 trials. Lilly also agreed to buy three vaccine developers (Curevo, LimmaTech Biologics, and Vaccine Company) in deals totaling up to $4 billion, expanding its focus on infectious diseases.
- STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly reported a 62% reduction in LDL cholesterol levels in a Phase 1 trial using its gene-editing therapy, VERV-102, acquired from Verve Therapeutics. The therapy showed no serious adverse events, marking a significant safety improvement over Verve's previous shelved candidate. The treatment is positioned as a potential one-time solution for preventing heart disease.